A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases
News Apr 10, 2013
SARomics Biostructures, Prestwick Chemical and ProQinase together with the University of Turin, Italy, the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science, Israel, and the TechMedIll platform of the University of Strasbourg, France, announce that they have created the Translational Kinase Tumor Inhibitor Discovery Consortium (TAKTIC), funded with €1.1 million by the EU 7th Framework Program “Research for the Benefit of SMEs”.
Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium brings together the unique and proprietary technologies of three SMEs and their knowhow in the field of drug discovery. To this are coupled the extensive expertise in medicinal chemistry, kinase biochemistry and biology of the University of Turin as well as the state-of-the-art high throughput platform for protein expression and crystallization of the Israel Structural Proteomics Centre. The merging of the highly complementary capabilities of the six partners within the TAKTIC Consortium enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases.
“We are excited to coordinate a frontline project of these dimensions, which brings together companies and academic researchers with impressive track records within their respective fields.” says Prof. Salam Al-Karadaghi, project coordinator and Director of Business Development at SARomics Biostructures.
“This exciting project fits with our corporate strategy to generate future value through collaborations with top-tiered SMEs and academic groups” added Prof. Thierry Langer, CEO at Prestwick.
“ProQinase is very pleased to join this attractive project since it brings together complementary expertise from biotech industry and academia creating highly promising synergies in the development of novel anti-cancer drugs” explained Christoph Schächtele, Managing Director of ProQinase.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
Gut Microbes May Contribute to Depression and AnxietyNews
Like everyone, people with type 2 diabetes and obesity suffer from depression and anxiety, but even more soREAD MORE
Disease-Fighting 'Warheads' Hidden in BacteriaNews
Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018